ARTICLE | Company News
Calypso Biotech, iDD Biotech deal
May 20, 2013 7:00 AM UTC
iDD Biotech granted Calypso exclusive, worldwide rights to CALY-002, a humanized mAb, to treat refractory celiac disease. iDD received an upfront payment and is eligible for milestones, plus royalties. CALY-002 is in preclinical development, and Calypso plans on starting clinical testing by year end 2015 or early 2016. The biotech declined to disclose the target of the mAb or financial details, and iDD could not be reached. ...